Alcon sees 2020 dividend, bolt-on purchases in life after Novartis

Alcon sees 2020 dividend, bolt-on purchases in life after Novartis


Alcon, which made the announcement on Tuesday ahead of an investor day in New York, is being jettisoned from Novartis's portfolio as Chief Executive Vas Narasimhan focuses on new drugs, not the surgical devices and contact lenses that Alcon makes. The eye care unit, whose sales returned to growth in 2017 after Novartis was forced to invest millions in sales and service staff to arrest declines, could be valued between $20 billion and $30 billion, Novartis officials have said, when it is spun off to shareholders in the first half of 2019.



from Biotech News
Share:

Комментариев нет:

Отправить комментарий

Pharmacy News Digest

Архив блога